Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

J Diabetes. 2016 Jan;8(1):166-9. doi: 10.1111/1753-0407.12332. Epub 2015 Nov 17.
No abstract available

Keywords: hypoglycemia; insulin glargine; insulin peglispro; short-acting insulin; type 1 diabetes mellitus.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cross-Over Studies
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Glycemic Index
  • Humans
  • Hypoglycemia / prevention & control*
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Glargine / therapeutic use*
  • Insulin Lispro / therapeutic use*
  • Prognosis
  • Time Factors

Substances

  • Hypoglycemic Agents
  • Insulin Lispro
  • Insulin Glargine

Associated data

  • ClinicalTrials.gov/NCT01049412